OR WAIT null SECS
September 12, 2017
The company has extended its presence in the US market to support its growing business in the region.
September 07, 2017
Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.
September 06, 2017
Pfizer’s Mylotarg, an anti-body drug conjugate once voluntarily withdrawn, returns to the market under a new dosing regimen for treating leukemia.
September 02, 2017
FDA works with industry on strategies for assuring high-quality regenerative medicines.
Modeling tools help process engineers optimize a biopharmaceutical facility’s capacity.
Innovation speeds discovery, drives down costs, and improves productivity.
August 30, 2017
FDA approves Novartis’ CAR-T therapy, marking the first time a cell therapy based on gene transfer has been approved in the United States for any indication.
August 29, 2017
Gilead will gain a robust pipeline of cell therapy products, with one lead candidate, a CAR T therapy, anticipated to gain FDA approval in the fourth quarter.
AstraZeneca and Takeda will partner to develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
August 24, 2017
FDA grants priority review for emicizumab, an investigational bispecific monoclonal antibody, for treating hemophilia A with factor VIII inhibitors.